文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

增强自噬可改善脓毒症诱导的神经肌肉功能障碍并与乙酰胆碱受体定性改变相关

Enhancing Autophagy Protects Against Sepsis-Induced Neuromuscular Dysfunction Associated with Qualitative Changes to Acetylcholine Receptors.
PubMed 文献 · Shock · 2019-01-01
一句话结论在盲肠结扎穿孔脓毒症大鼠模型中,雷帕霉素增强自噬可下调γ-和α7-乙酰胆碱受体、改善7天神经肌肉功能与生存率,作者认为脓毒症早期增强自噬是治疗脓毒症性肌病的潜在策略。

研究在雄性Sprague-Dawley大鼠盲肠结扎穿孔(CLP)脓毒症模型中观察胫骨前肌神经肌肉功能障碍,CLP后24小时出现全身及局部炎症,自噬启动相(LC3II)即刻激活并持续至24小时,降解相(p62)在4小时短暂升高后受抑至24小时;NRG-1先升高后降至低于假手术组,γ-和α7-乙酰胆碱受体在CLP后8和16小时可检测到并持续升高至24小时。用雷帕霉素增强自噬可激活自噬、限制CLP诱导的全身促炎反应和血液细菌负荷而不影响局部炎症反应、上调NRG-1、下调γ-和α7-乙酰胆碱受体,并改善7天神经肌肉功能与生存率;3-甲基腺嘌呤抑制自噬则增强局部炎症反应并恶化7天神经肌肉功能。作者结论认为自噬受损可能参与脓毒症诱导的神经肌肉功能障碍,雷帕霉素增强自噬在脓毒症早期(24小时)及慢性期(7天)改善胫骨前肌功能,脓毒症后尽早增强自噬是治疗脓毒症性肌病的潜在策略。

要点

  • 雄性Sprague-Dawley大鼠CLP后24小时胫骨前肌出现神经肌肉功能障碍,伴全身及局部炎症。
  • CLP后自噬启动相(LC3II)即刻激活并持续至24小时,降解相(p62)在4小时短暂升高后受抑至24小时。
  • 雷帕霉素增强自噬可限制CLP诱导的全身促炎反应和血液细菌负荷、不影响局部炎症反应,并改善7天神经肌肉功能与生存率。
  • 3-甲基腺嘌呤抑制自噬可增强局部炎症反应并恶化7天神经肌肉功能。
  • 雷帕霉素上调NRG-1并下调γ-和α7-乙酰胆碱受体,作者认为脓毒症后尽早增强自噬是治疗脓毒症性肌病的潜在策略。

适用人群与场景

  • 雄性Sprague-Dawley大鼠盲肠结扎穿孔(CLP)脓毒症模型,观察胫骨前肌神经肌肉功能。

处置流程与药物剂量

  • 雷帕霉素用于增强自噬,3-甲基腺嘌呤用于抑制自噬,二者为原文所述经典药物;原文未给出剂量、途径、频次或疗程。

研究设计与关键结果

  • 研究类型为动物实验(大鼠CLP脓毒症模型),观察CLP后24小时胫骨前肌神经肌肉功能障碍及自噬、NRG-1、γ-和α7-乙酰胆碱受体的变化。
  • CLP后自噬启动相(LC3II)即刻激活并持续至24小时;降解相(p62)在4小时短暂升高后受抑至24小时。
  • NRG-1先升高后降至低于假手术组水平;γ-和α7-乙酰胆碱受体在CLP后8和16小时可检测到,水平持续升高至24小时。
  • 雷帕霉素激活自噬,限制CLP诱导的全身促炎反应和血液细菌负荷而不影响局部炎症反应,上调NRG-1,下调γ-和α7-乙酰胆碱受体,改善7天神经肌肉功能与生存率。
  • 3-甲基腺嘌呤增强局部炎症反应、抑制自噬、恶化7天神经肌肉功能。

证据类型、等级与局限

  • 证据类型:动物实验(雄性Sprague-Dawley大鼠CLP脓毒症模型)。
  • 作者结论:自噬受损可能参与脓毒症诱导的神经肌肉功能障碍;增强自噬是治疗脓毒症性肌病的潜在策略。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文为动物实验,作者认为脓毒症后尽早增强自噬是治疗脓毒症性肌病的潜在策略;原文未给出临床推荐或剂量方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Sepsis-induced myopathy is a heavy burden for patients during respiratory failure as well as after discharge, which could be characterized with qualitative changes to nAChR in a rat model of sepsis, regulated by NRG-1. Autophagy is an innate immune defense mechanism against microbial challenges. We found neuromuscular dysfunction in anterior tibial muscle of male Sprague-Dawley rats 24 h after cecal ligation and puncture (CLP). CLP resulted in increased systemic and local inflammation in anterior tibial muscle tissue. The start-up phase of autophagy, as measured by LC3II, was activated immediately after CLP and continued until 24 h; the degradation phase was suppressed until 24 h, after a brief increase at 4 h (revealed by p62). NRG-1 first increased, and then decreased to a level lower than that in the sham group. Meanwhile, expression of γ- and α7- acetylcholine receptors was detected at 8 and 16 h after CLP; levels increased continuously until 24 h. Subsequently, we investigated the significance of autophagy in CLP-induced neuromuscular dysfunction by treatment with rapamycin or 3-methyladenine, which were classical pharmaceuticals for enhancing or suppressing autophagy. Rapamycin activated autophagy, limited the CLP-induced systemic pro-inflammatory response and blood bacterial load without affecting local inflammatory response, upregulated NRG-1, downregulated γ- and α7-acetylcholine receptors, and improved 7-day neuromuscular function and survival rate. In contrast, 3-methyladenine enhanced local inflammatory response, suppressed autophagy, worsened 7-day neuromuscular function. We conclude that impaired autophagy may contribute to sepsis-induced neuromuscular dysfunction in young male rats. Enhancing autophagy with rapamycin alleviated qualitative changes to acetylcholine receptors without triggering local anti-inflammatory response and improved anterior tibial muscle function in septic early phase (24 h) as well as in septic chronic phase (7d). Enhancing autophagy soon after sepsis is a potential strategy for treatment of sepsis-induced myopathy.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Chen J, Min S, Xie F, et al. Enhancing Autophagy Protects Against Sepsis-Induced Neuromuscular Dysfunction Associated with Qualitative Changes to Acetylcholine Receptors. Shock. 2019. PMID: 30286033. doi:10.1097/SHK.0000000000001189

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。